BACKGROUND Aesthetically, striae distensae (SD) are a source of great concern. No treatment modality is currently considered the gold standard. However, studies of nonablative fractionated lasers (NAFLs) have been promising.
S tretch marks, or striae distensae (SD), are a common occurrence in the general population and aesthetically, a source of great concern and psychological distress for many. They are generally acquired in the context of rapid weight changes, growth spurts in puberty, corticosteroid use, or pregnancy. Lesions typically affect the abdomen and breasts in pregnancy-related striae, whereas pubertyrelated striae classically affect the outer thighs and lumbosacral region in men and the buttocks, thighs, upper arms, and breasts in women. 1 Regardless of their anatomical location, striae are clinically and histologically known to progress through different evolutionary stages. Initially, lesions appear as red and slightly raised "striae rubra" (SR) before becoming white or skin-colored, atrophic "striae alba" (SA). The histologic features undergo a corresponding progression over time. An acute superficial and deep perivascular lymphocytic infiltrate eventually yields to an end-stage epidermal thinning with loss of collagen and elastic fibers. 2, 3 between SD evolution and scar remodeling, suggesting that laser-based therapy may be beneficial. Early studies using nonablative fractionated lasers (NAFLs) to treat striae have been promising. [8] [9] [10] [11] [12] The microscopic columns of thermal injury induced by NAFLs creates a wound-healing response that results in tissue remodeling through neocollagenesis and reorganization of elastin fibers. The intervening zones of untreated tissue provide a nutritional reservoir, which allow for reduced downtime and improved safety.
The purpose of this study was therefore to evaluate and compare the clinical and histopathologic efficacy and also the safety of a 1540-nm NAFL (Icon1540; Cynosure, Westford, MA) and the 1410-nm NAFL (Emerge1410; Cynosure) for the treatment of SD.
Materials and Methods
The study protocol was approved by the Thomas Jefferson University Institutional Review Board (IRB) and conducted in accordance with the provisions of the Declaration of Helsinki and Health Insurance Portability and Accountability Act.
Ten consecutive patients with SR and SA of the abdomen were enrolled. Males and females with Fitzpatrick skin Types I to VI between the ages of 18 and 55 years were screened for participation. Patients who had treated their SD within the preceding 6 weeks and those with preexisting cutaneous diseases were excluded.
Once screened, each participant was given informed consent using an IRB-approved protocol at the enrollment visit. This session also included a medical history interview and questionnaire, Fitzpatrick skin type rating, and characterization of the location and type of SD present. Patients were instructed to refrain from using any treatments to the study area, topical or otherwise, except as directed by the study physicians. Participants were also asked to protect the study area from excessive sunlight and to apply a broad-spectrum sunscreen (SPF 30 or greater).
A total of 6 treatments, at 3-to 6-week intervals, and a follow-up visit of 90 days after the final treatment were undertaken. Before each treatment, high definition standardized photographs were taken using a Nikon D80 camera with a standard lens (Nikon, Tokyo, Japan). Settings were f7.1, ISO 1/60. Lighting was provided by both camera flash and 2 dummied remote flashes. The remote flashes were suspended from a study-specific, custom lighting stand on a boom suspended at a 30°angle from the vertical mast, which was secured at 90°to the floor mounts. A mounted 2-dimensional leveling device ensured consistency of these measurements. Patients were positioned for photographs (front-on, 45 degrees-left, and 45 degrees-right) using stationary landmarks. A photographer's felt served as the backdrop. Patients also completed a questionnaire that inquired about the tolerability of the procedure, treatment results, and the duration and acceptability of side effects.
Before the laser procedure, a topical anesthetic (lidocaine 30% ointment, compounded by Crown Pharmacy, Philadelphia, PA) was applied under occlusion with saran wrap for 60 minutes and subsequently washed off. The striae treatment area was determined by an imaginary line from the xyphoid process to the pubis symphysis, bisecting the abdomen. Striae on the right side of each patient's abdomen were treated using the 1540-nm NAFL with 2 handpieces, XD (extra deep) and XF (extra fast) handpieces, with the following settings: XD-50 J/cm 2 , 15 milliseconds, 2 passes; XF-50 J/cm 2 , 15 milliseconds, 2 passes for a total 25% density. Striae on the left side of the abdomen were treated using the 1410-nm NAFL with the following settings: 30 J/cm 2 , 5 passes, 16% density.
Although patients were blinded to these details, the treating physicians were not. The precise area of SD was targeted during treatments to minimize potential postinflammatory hyperpigmentation (PIH) of surrounding normal skin; however, the whole affected area was treated in patients whose lesions were too numerous or dense in nature. With each visit, patients were asked about the duration and intensity of posttreatment erythema, edema, and pruritus. They also rated the pain of the 2 treatments from 0 (no pain) to 10 (extremely intolerable pain). All adverse events were recorded and graded. If necessary, patients were given prescriptions to alleviate pruritus or PIH by
applying triamcinolone 0.1% ointment and/or hydroquinone 4% cream twice a day to the affected area in between treatment sessions.
Two of the 10 patients were selected by a computer randomizer to have a total of 5 punch biopsies taken from representative lesions on both halves of the abdomen. One biopsy was taken at baseline (before treatment) from the most representative SD on the whole abdomen. Immediately after the first treatment, 2 biopsies were taken, 1 from each side. Three months after the final treatment, 2 more biopsies were taken from the same representative lesions as those used for previous specimen procurement. These were positioned as closely as possible, yet at a distance sufficient to avoid harvesting scar tissue engendered by previous biopsy. All lesions were closed in a standard fashion using 4-0 prolene and managed with standard wound care procedures, including plain petroleum jelly and dressings, until healed. Specimens were processed and stained with hematoxylin and eosin (H&E), trichrome, and Verhoeff-Van Gieson (VVG) at the same time.
Clinical SD improvement was graded subjectively by each patient and objectively by 2 blinded nonstudy dermatologists using a pre-established quartile clinical scale (Table 1) . Histologic improvement was graded objectively by 2 nonstudy dermatopathologists using a pre-established pathology quartile scale ( Table 2) .
Results

Subject Demographics
Ten patients were initially enrolled with 9 (8 females and 1 male) completing the study. One patient was excluded during treatment as she became pregnant.
Fitzpatrick skin Types I to IV were enrolled, with Type II being the most common skin type treated. The average age of the treated patients was 32.5 6 8.8. On average, patients had their striae for 10.5 6 9.5 years before treatment, and no patient had a history of previous striae treatment. Striae were all located on the abdomen; 8 patients had central abdominal striae while 2 patients had lateral abdominal striae. Both SR (n = 8) and SA (n = 2) were treated.
Clinical Improvement in Striae
On blinded evaluation of clinical photographs, all 9 patients demonstrated bilateral improvement in 90 days after treatment ( Figure 1A,B ). Twenty-eight percent of the 1410 nm-treated and 33% of the 1540 nm-treated patients were rated as having "good" or "excellent" improvement. Seventy-two percent of the 1410 nm-treated and 66% of the 1540 nm-treated patients were rated as having "mild" or "fair" improvement. Quantitative equivalents of the ratings are provided in Table 1 . Overall, the difference in efficacy between the 2 laser modalities was not statistically significant (p = .747).
Histopathological Analysis
On H&E stain, all biopsies obtained in 90 days after treatment showed an increase in epidermal thickness, dermal thickness, and collagen density compared with the baseline biopsies. On average, 90 days after treatment, the blinded dermatopathologists rated the increase in epidermal thickness, dermal thickness, and collagen density as 1.75, 1.50, and 1.75 for the 1410 nm-treated side using the pre-established pathology scale. In comparison, the 1540 nm side scores were 2.00, 1.75, and 2.00, respectively. Differences between the 1410 nmand 1540 nm-treated sides were not statistically significant (p = .85, p = .86, and p = .83). Both the Trichrome-and VVG-stained posttreatment biopsy specimens revealed an increase in collagen and elastin from baseline. On VVG-stained biopsies after treatment, both 1410 nm-and 1540 nm-treated biopsies were assigned a score of 2.25 compared with baseline. On Trichrome-stained biopsies after treatment, 1540 nm-treated biopsies scored 2.50 while 1410 nm-treated biopsies scored 2.0. These differences, however, were not statistically significant.
Representative increases in Trichrome-and VVGstained specimens after treatment are shown in Figure  2A ,B,C and in Figure 3A ,B,C.
Patient Satisfaction Rating
At 90-day posttreatment visit, 71.4% of patients were "very satisfied" and 28.6% were "moderately satisfied" with the treatment. Only 1 of the subjects described the overall improvement as "fair." One subject rated the overall improvement at the follow-up visit as "excellent" whereas the remainder of the subjects described the overall improvement as "good" (n = 4) or "very good" (n = 3). When subjects were asked to quantify the improvement in their SD at 90-day posttreatment visit, most chose an improvement from 50% to 74% (range: 11%-74%). When asked if they would recommend the treatment to a friend, 57.1% specified "definitely would" and 42.9% specified "probably would."
Side Effects
The treatment was well tolerated with no significant long-lasting adverse effects. (Figure 4A,B) . The duration of treatment sessions was also substantially longer on the 1410 nm-treated side compared with the 1540 nmtreated side as a result of the scanning mode and higher number of passes. All reports of PIH were temporary and none of the patients had PIH at the 3-month follow-up visits.
Discussion
The treatment of SD has long been a challenge for dermatologists and their patients. The broad variety of candidate therapies described in the literature reflects the difficult nature of treating this common condition. Tretinoin and other topical medications typically yield unsatisfying results. 6, 7 Lasers and light-based therapies, such as the 585-nm pulsed dye laser 13, 14 and intense pulsed light, 15 also showed inconsistent promise until the advent of fractionated lasers.
Nonablative fractionated lasers are now a promising treatment modality for treating SD. The precise narrow zones of thermal injury created by NAFLs, while leaving the stratum corneum intact and the intervening tissues unaffected, facilitate rapid healing. These Few studies, however, systematically investigate the clinical efficacy and safety of 1540-nm laser devices in the treatment of SD. Moreover, no literature exists using a 1410-nm NAFL and also comparing it to 1540-nm NAFL. De Angelis and colleagues 8 were the first to examine the treatment of SD using the fractionated 1540-nm erbium: glass laser in 51 patients. Blinded reviewers analyzed 14 images and reported a mean improvement of 50% to 75%. In 2014, Malekzad and colleagues investigated the safety and efficacy of treating SD in 10 female subjects of Fitzpatrick skin Types III to V using a fractionated 1540nm laser. There was a significant improvement clinically in striae between the 4-week treatment and the 16-week treatment, with durable 3-month posttreatment improvement compared with baseline. 16 More recently, Alves and colleagues reported clinical improvement in 4 patients with Fitzpatrick skin Type IV who were treated with the fractionated 1540-nm laser. 17 The use of both the 1540-nm and 1410-nm laser in the split abdomen study resulted in similar improvement of SD in all 9 patients who completed the study. The 2 blinded nonstudy dermatologists rated the clinical improvement positively on both treated sides. On average, they rated the 1540 nm-treated side higher, with a greater portion of patients receiving "good" or "excellent" ratings. This difference in the clinical ratings between the 2 lasers, however, did not reach statistical significance.
Histopathologically, biopsied specimens supported the clinical improvements seen in all subjects. Posttreatment biopsies demonstrated increases in epidermal thickness, dermal thickness, and collagen density. Although the improvements were not statistically significant between the 2 lasers, there was a trend toward greater improvement on the 1540 nm-treated side compared with the 1410 nm-treated side.
Subjects were satisfied with treatment efficacy with both lasers. Most patients were "very satisfied" (71.4%) with the treatment after 90 days with the remainder of the subjects "moderately satisfied" with the treatment. Moreover, when asked to quantify changes in their SD, most patients specified improvement ranging from 50% to 74%.
The treatment sessions were well tolerated and no significant adverse events were experienced by any of the subjects. As anticipated, transient PIH was the most common side effect. Interestingly, average PIH was less substantial on the 1540 nm-treated side compared with the 1410 nm-treated side (Figure 4A,  B) . The scanning mode and the higher number of passes required for treatment with the 1410-nm laser may have contributed to this observation, although higher powered studies are required to determine whether this trend is clinically significant.
The study limitations include the small sample size; additional subjects are needed to determine whether these findings can be generalized. However, results from the pilot study add to the growing evidence suggesting that SD respond favorably to the use of NAFLs. Larger studies are still needed to optimize treatment settings, end points, and intervals.
Conclusion
The treatment of SD remains a challenge for both dermatologists and their patients. Nonablative fractionated lasers are now a promising treatment modality for treating SD. This study is, to our knowledge, the first in comparing the clinical and histopathologic efficacy and also the safety of the 1540-nm NAFL and the 1410-nm NAFL for the treatment of SD. All 9 patients who completed the study showed both clinical and histopathological improvements in their SD posttreatment. The 1540 nm-treated side showed a trend toward greater clinical and histopathological improvement compared with the 1410 nm-treated side, but the study was not sufficiently powered to determine significance. Both lasers were well tolerated by patients and PIH was transient in affected patients.
